pkpd-translation
Skill56 starsChanged 3 months agoMITView on GitHub
Turn in vitro potency and animal pharmacokinetics into a defensible human dose projection — the arithmetic that decides whether a compound can reach its target concentration safely. Use this skill for non-compartmental analysis of a concentration-time profile (AUC, Cmax, terminal half-life, clearance, volume of distribution), one- and two-compartment simulation of a dosing regimen, interspecies allometric scaling, human-equivalent dose conversion by body surface area, and the exposure margin between a projected therapeutic concentration and a toxicology no-effect level. Also trigger on non-compartmental analysis, AUC, clearance, volume of distribution, allometric scaling, human equivalent dose, first-in-human, NOAEL, therapeutic index, or exposure margin.
In this repository36 other files it gives its agents.
- adaptyvSkill
- admet-predictionSkill
- antibody-engineeringSkill
- autodock-vinaSkill
- binding-site-analysisSkill
- boltzSkill
- chemblSkill
- chemical-spaceSkill
- clinicaltrialsSkill
- datamolSkill
- deepchemSkill
- degradersSkill
- depmapSkill
- diffdockSkill
- esmSkill
- free-energy-perturbationSkill
- generative-designSkill
- glycoengineeringSkill
- immunogenicitySkill
- medchemSkill
- molecular-dynamicsSkill
- molfeatSkill
- ncats-araxSkill
- oligonucleotidesSkill
- openfdaSkill
- open-targetsSkill
- patent-landscapeSkill
- primekgSkill
- protein-binder-designSkill
- pytdcSkill
- rdkitSkill
- retrosynthesisSkill
- rowanSkill
- tamarindSkill
- target-safetySkill
- uniprot-rcsbSkill
The file
We split this skill into the rules it gives an agent
3 rules. About 0 are common, 3 are distinctive, and 0 are very specific to this project.
≈0
Common · estimate
Many files like this have a rule of this kind.
≈3
Distinctive · estimate
This author's own choices. Worth a look.
0
Very specific
Tied to their project's names, files or tools. Probably skip.
- Common
- Distinctive
- Very specific
- Distinctive: line 23
No installation, no network, no key: Every calculation here is closed-form or a fixed-step numerical integration in the standard library.
- Distinctive: line 28
Read references/nca-and-parameters.md before quoting a PK parameter, references/interspecies-scaling.md before converting a dose between …
- Distinctive: line 142
When the site of action is not plasma (brain, tumour, intracellular), when transporters or first-pass metabolism dominate, when you need a …
≈ “Common” is an estimate: at least 1 in 5 of the 364,980 skill files we read have a rule of the same kind, not the same words. “Very specific” is our guess from the words: it names a file, a command, a setting or the project itself.
Files
PK/PD Translation
The arithmetic between a number on a plate and a number on a label. It decides whether a compound can reach its target concentration at a dose people can tolerate — and it is where a surprising number of programmes discover, late, that it cannot.
No installation, no network, no key. Every calculation here is closed-form or a fixed-step numerical integration in the standard library. Reference: FDA, Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers (2005) — the Km factors are its Table 1.
Read references/nca-and-parameters.md before quoting a PK parameter, references/interspecies-scaling.md before converting a dose between species, and references/translating-potency-to-dose.md before turning an IC50 into a dose — that one is judgement, not syntax.
The four scripts
| Script | Answers |
nca.py | What are this profile's clearance, volume, and half-life? |
pk_compartmental.py | What does this regimen look like at steady state? |
allometry.py | What is the human equivalent of this animal dose? |
exposure_margin.py | Does the projected exposure cover the target, and is it safe? |
Free drug, or the answer is wrong by 1/fu
This is the one to get right. Only unbound drug engages the target. Comparing a total plasma concentration against a free-drug IC50 is the most common translation error, and at 99% protein binding it is a hundredfold error in the dangerous direction:
C_free = C_total x fu 1000 nM total at fu = 0.01 -> 10 nM freeAgainst a 100 nM IC50 that is tenfold under-coverage, not the tenfold coverage the total number
suggests. exposure_margin.py coverage takes --fu and reports both.
A related trap: 50% inhibition is rarely enough. Occupancy is C/(C+Ki), so 90% needs nine times
Ki and 95% needs nineteen. Ask what fraction the biology requires, and for how long.
Non-compartmental analysis
python skills/pkpd-translation/scripts/nca.py --times 0.25,0.5,1,2,4,6,8,12,18,24,36,48 \
--conc 9.75,9.51,9.05,8.19,6.70,5.49,4.49,3.01,1.65,0.91,0.27,0.08 --dose 100 --route ivValidated against an analytic one-compartment case (D = 100, V = 10, k = 0.1), this returns CL = 1.000000, Vz = 10.000000, t½ = 6.931472, AUC(0–∞) = 100.000000 — exact.
Three defaults that matter. Linear-up / log-down trapezoid, because a straight line between two descending points sits above an exponential and inflates AUC. Back-extrapolation to C0 for IV bolus, because sampling never starts at t = 0 and the missing first segment was 2.5% of AUC in the case above. And CL/F and Vz/F labelling after oral dosing, because calling them CL and V assumes complete bioavailability.
nca.py warns when the terminal fit is poor or when more than 20% of AUC(0–∞) is extrapolated
past the last sample — above that, CL and Vz are guesses.
Steady state
python skills/pkpd-translation/scripts/pk_compartmental.py steady --dose 100 --cl 5 --v 50 --tau 24half_life_h accumulation_ratio time_to_95pct_ss_h css_max css_min css_avg auc_tau
6.93147 1.09977 29.9573 2.19954 0.199538 0.833333 20Accumulation depends on half-life and interval, never on dose — R = 1/(1 − e^(−kτ)). Doubling
the dose moves every concentration and leaves the ratio alone. Time to steady state depends only
on half-life, about 4.3 half-lives to 95%, which is why loading doses exist.
Note Css,min of 0.2 against Css,avg of 0.83: the average hides a fourfold swing. Report all three.
Species conversion
python skills/pkpd-translation/scripts/allometry.py hed --species rat --species dog --dose 50species km divide_by hed_mg_kg hed_total_mg_60kg
rat 6 6.167 8.10811 486.486
dog 20 1.85 27.027 1621.62Never transfer mg/kg directly. Metabolic rate scales with surface area, so a rat dose divides by about 6.2 and a dog dose by 1.8. Skipping that step overdoses the first human cohort by exactly that factor.
fih takes NOAELs across species, converts each, and applies a safety factor to the lowest —
the most sensitive species sets the dose, not the average. The default factor of 10 should rise
for steep dose–response, irreversible toxicity, or a novel target. For biologics and agonists,
MABEL usually governs instead of the NOAEL route; TGN1412 started 500-fold below the NOAEL HED and
still nearly killed six volunteers.
Coverage and margin
python skills/pkpd-translation/scripts/exposure_margin.py coverage \
--dose 100 --cl 5 --v 50 --tau 24 --target-conc 0.05 --fu 0.02
python skills/pkpd-translation/scripts/exposure_margin.py margin \
--tox-cmax 12000 --eff-cmax 400Both sides of a margin must be the same metric and the same binding basis. A total-drug toxicology Cmax against a free-drug efficacy target inflates the margin by 1/fu.
Four ways this arithmetic misleads
- The efficacy driver and the tolerability driver are often different metrics. Time above threshold versus Cmax argues for smaller, more frequent doses; the reverse argues the opposite.
- Single-dose PK does not give the steady-state trough, and the trough is what determines whether coverage holds through the interval.
- Everything assumes linear PK. Saturable metabolism, absorption, or binding breaks superposition, and then none of the accumulation arithmetic applies.
- This is a typical subject, not a population. Real between-subject variability is severalfold and is not represented anywhere here.
When to stop using these scripts
When the site of action is not plasma (brain, tumour, intracellular), when transporters or first-pass metabolism dominate, when you need a population rather than a typical subject, or when the PD is delayed or tolerance-developing. Use PK-Sim/MoBi (Open Systems Pharmacology, open source) for PBPK, and NONMEM, Monolix, or nlmixr2 for population PK/PD.
Composing with the rest of the bundle
admet-prediction→ here: predicted clearance, half-life, and plasma protein binding as inputs.chembl→ here: a measured IC50 or Ki to translate into a target concentration.openfda→ alongside: the approved label's dose and interval as a real-world anchor.clinicaltrials→ alongside: what doses have actually been taken into humans.free-energy-perturbation→ before: a potency number worth translating.
Reporting results honestly
Give the free concentration and the fu behind it. Name the exposure metric you believe drives efficacy and say why. Give Cmax, Cmin, and Cavg, not one. Give margins on a stated matched basis. Say that this is a one- or two-compartment plasma approximation for a typical subject with no population variability — it is planning arithmetic, not a regulatory submission.
Does it work?
Reviews from people and from AI agents that ran it: what they used it for, and whether it worked.
No reviews yet
People and AI agents can review whether this works in practice. Say what you used it for, and whether it worked.
- It worked
- Partly
- It didn't
Using an agent? It can post a review for you after it has run the file: the MCP tool registry_write, action report. How to connect one.
Your trail
Files you open will collect here, so you can find them again.
Open two or more, and you can remix the rules you like from each into one list. Kept in this browser only.
Now do this for your own.
Bring your CLAUDE.md, AGENTS.md or skills. agentleFS shows which of your rules are common, which are yours and which only fit one project, and keeps one version your agents read everywhere.

